VirMedica’s dynamic leadership team is a unique convergence of recognized leaders and experts across several disciplines with a variety of executive-level experience and complementary competences critical to redefining the patient access ecosystem for biopharmaceutical products, including corporate strategy, business development, commercialization, sales, manufacturing, pharmacy services, benefits and reimbursement, and manufacturing.
Greg has served as CCO of VirMedica since January 2015 and brings over 25 years of expertise in the insurance reimbursement and benefits management arena. Prior to joining VirMedica, Greg founded TransEngen, Inc., a leading provider of automated, real-time benefits verification service. As chief commercial officer of VirMedica, Greg oversees product strategy and commercialization efforts for the Company’s integrated platform for automated HUB services, patient case management and specialty pharmacy operations. Greg has previously served as chief operating officer at Aon’s National Healthcare Practice and HealthMarket. Greg holds a B.A. in Economics from Harvard University.
John, also known as Jay, has served as CFO of VirMedica since September 2015 and has more than 25 years of expertise in driving revenue growth for leading global healthcare and technology organizations. Prior to VirMedica, Jay was the chief financial and administrative officer for AdvantEdge Healthcare Solutions, a global healthcare analytics and services organization. He also served as chief financial officer and treasurer for InfoLogix, Inc., a publicly-traded healthcare-centric mobile software and solutions provider, which was acquired by Stanley Healthcare, with Jay leading the transaction. He has also held CFO roles at leading public medical device and healthcare services firms including Clarient, Inc., and Daou Systems, Inc. In addition, he has held key senior executive roles with MEDecision, Inc., HealthOnline, Inc., and the Center for Health Information. Jay is currently a member of the board of directors and chairman of the Finance Committee for the Drug Information Association. He previously served as the chairman of the board of directors for AdvantEdge Healthcare Solutions Private Limited, based in Bangalore, India. Jay holds a B.S. and a Master’s degree in Business Administration from the University of Maine.
Randall, also known as Buck, has served as COO of VirMedica since January 2015. He brings more than 20 years of healthcare technology leadership experience, including successful direction of regional, national, startup, turnaround and M&A activities. Prior to joining VirMedica, Buck acted as chief executive officer and president at TransEngen, Inc. As chief operations officer of VirMedica, he oversees multiple functional areas and teams across the business, including sales and business development, strategic partnerships, customer relations and marketing. Buck previously served as an executive vice president of business development at ABILITY Network Inc., as executive vice president of Healthport, LLC, and held executive-level positions of increasing seniority at Ability Network, Health Port, Emdeon Practice Services and National Medical Management Corporation.
John has been Chairman since November 2015 and is a recognized leader in the biopharmaceutical industry, bringing more than 30 years of experience at leading global organizations – including Johnson & Johnson, Eli Lilly & Company, ImClone and Pfizer. John works closely with VirMedica’s seasoned leadership and shares his recognized industry expertise and entrepreneurial spirit with the team. He currently serves as chairman of Strongbridge Biopharma plc, lead independent director of Sucampo Pharmaceuticals, Inc., and as a member of the board of directors of Cempra Pharmaceuticals, Inc., Histogenics Corporation and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ. John holds a B.S. from the East Stroudsburg University of Pennsylvania.
Dean, president of D2 Pharma Consulting, LLC was appointed to the board of directors in January 2015. He brings more than 25 years of strategic sales, marketing and management experience across both the consumer product and pharmaceutical arenas that spans several Fortune 500 organizations, including Express Scripts, Cardinal Health and U.S. Healthcare. Dean is a co-founder of D2 Pharma Consulting, a firm which provides strategic outsourced solutions for the commercialization, distribution and marketing of pharmaceuticals, medical devices and biologic medications. Dean has worked with over 200 companies in developing strategic and tactical solutions in the areas of product distribution and reimbursement. He has previously served as president of the not-for-profit Regulatory Harmonization Institute and currently serves on the board of trustees of STAGES St. Louis. Dean holds a B.A. from the University of Oklahoma and a MBA from the Keller Graduate School of Management.
Appointed in January 2015, David is general partner at Petra Capital Partners and has nearly 20 years of experience in private equity and mergers and acquisitions in the healthcare, information technology and business services sectors. David currently serves on the board of directors for Clinipace Worldwide, Lineagen, New Century Hospice, Opportune IT Healthcare Solutions, SUN Behavioral Health and Urgent Team. He previously served on the board of directors for many successful growth companies, including SpecialtyCare (sold to American Securities), US Healthworks (sold to Dignity Health), Televox Software (sold to West Corp.), Appriss (sold to Bain Capital), Synhrgy (sold to Mercer), Nuvox Communications (sold to Windstream) and Salveo Specialty Pharmacy (sold to Catamaran). David holds a B.A. from Washington & Lee University.
Appointed in January 2015, David brings more than 25 years of retail, hospital, home infusion and specialty pharmacy experience to VirMedica. As executive vice president, Specialty Pharmacy Services at CVS Caremark for more than two decades, David was responsible for a robust $8 billon specialty unit during a period of extreme innovation and growth in the industry. He currently serves on the board of directors for BioScrips, Inc. and Global Healthcare Integrators, and previously served as a member of the board of directors of Salveo Specialty Pharmacy, Inc. David holds a B.S. in Pharmacy from the University of Illinois at Chicago.
Appointed in January 2015, Garheng is founder and managing partner of HealthQuest Capital and has nearly 20 years of clinical and technical experience in creating and building high-growth and innovation-based healthcare businesses. He currently serves on the board of directors of Alimera Sciences, Castle Biosciences, Cempra, Duke University Medical Center, First Aid Shot Therapy, Histogenics, Laboratory Corporation of America, Strongbridge Biopharma plc and Trice Medical. He previously served on the board of directors of SEBIO, the North Carolina Biotechnology Center and numerous industry groups. His early career included positions at GlaxoSmithKline, McKinsey and TherOx, before joining Intersouth Partners. Garheng received two undergraduate degrees in Chemical Engineering and Biological Sciences from Stanford University and earned his M.D., Ph.D. and MBA from Duke University.